Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 adolescent addendum of AMAM evaluating mirikizumab for moderate to severe active Crohn's disease
MOH_2021-06-16_010051Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirikizumab in Crohn's disease, sponsored by Eli Lilly and Company. Primary endpoint: Endoscopic and clinical remission through week 52. Started Apr 2021; status: completed.
02
Drugs
mirikizumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2021-06-16_010051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-06-16_010051.